Back to News
Market Impact: 0.35
ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
Source: zacks.com
Corporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
AbbVie raised its 2026 revenue and earnings outlook, citing momentum from Skyrizi, Rinvoq and neuroscience growth. Oncology milestones are also shaping the company’s prospects; the article provides no revised figures or milestone details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
ABBV0.70
More News
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear